Company Directory - Pharmaco

HUYABIO has now grown to be the leader in globalizing China’s pharmaceutical innovation. Meeting the challenge of tomorrow’s unmet medical needs requires utilizing the talents of Chinese researchers and helping to move their discoveries forward.

Halewood Chemicals is a producer & distributor of generic pharmaceuticals and raw materials. Founded as a wholesaler of medicines and raw materials, Halewood has since expanded into the development and licensing of own brand generic pharmaceutical finished products and over-the-counter (OTC) healthcare products.​

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

Heidelberg Pharma focuses on oncology and is the first company to use and develop the active ingredient Amanitin for cancer therapies. To do this, the company uses its innovative ATAC technology (Antibody Targeted Amanitin Conjugates) and uses the toxin's biological mechanism of action as a new therapeutic principle.

HERMES PHARMA is the leading expert in user-friendly dosage forms. We are a contract development and manufacturing organization (CDMO) which supports you across the entire pharmaceutical value chain - as a reliable and experienced partner.

Heumann Pharma is a large, well-established pharmaceutical company with a long history and a wide range of prescription and over-the-counter medicines. We continue to offer pharmaceutical products with proven active ingredients for a fair price.

With 3,100 different drugs for over 13 therapeutic areas, we are one of the largest providers of patent-free drugs in Germany.¹ Our wide range includes everything from over-the-counter OTC products to classic generics and innovative, biopharmaceutical products, so-called biosimilars.

On the changing stage of the international healthcare market, the name Holsten Pharma stands for high-quality pharmaceuticals that are manufactured according to exacting quality standards and for first-class medical care that is affordable.

Hyloris is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. We unlock the untapped potentials of existing medications to create new and improved treatment options.

IBEX Pharmaceuticals offers Contract Manufacturing services that include Seed Bank Creation, Fermentation and Biotransformation, Protein Purification and Formulation, Filling of Device Components and Lyophilization. We are ISO 13485 certified.

IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering unique and actionable insights.

From research to real world, IQVIA weaves together the technologies, resources, and expertise our customers need to rise to the next opportunity. To look beyond what’s expected. To advance human health with newfound confidence.

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions.

Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs.

Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

The Netherlands-based Intravacc is one of the world’s leading institutes for translational vaccinology.